About COP9 signalosome complex subunit 3
COP9 signalosome complex subunit 3 (COPS3) is a protein
from Homo sapiens identified by UniProt accession
Q9UNS2, 423 residues long.
MolForge cross-references it against 0 known binders and
55 disease associations.
Target properties
| Protein name | COP9 signalosome complex subunit 3 |
| UniProt accession | Q9UNS2 |
| Gene | COPS3 |
| Organism | Homo sapiens |
| Length | 423 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (55)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.42
- heel bone mineral density · score 0.31
- reticulocyte count · score 0.29
- mean corpuscular volume · score 0.29
- glioblastoma multiforme · score 0.23
- mean reticulocyte volume · score 0.22
- lung adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- neutrophil percentage of leukocytes · score 0.15
- diet measurement · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UNS2-F1 | alphafold | PREDICTED | 84.22 | — |
Amino-acid sequence (423 residues)
MASALEQFVN SVRQLSAQGQ MTQLCELINK SGELLAKNLS HLDTVLGALD VQEHSLGVLA VLFVKFSMPS VPDFETLFSQ VQLFISTCNG EHIRYATDTF AGLCHQLTNA LVERKQPLRG IGILKQAIDK MQMNTNQLTS IHADLCQLCL LAKCFKPALP YLDVDMMDIC KENGAYDAKH FLCYYYYGGM IYTGLKNFER ALYFYEQAIT TPAMAVSHIM LESYKKYILV SLILLGKVQQ LPKYTSQIVG RFIKPLSNAY HELAQVYSTN NPSELRNLVN KHSETFTRDN NMGLVKQCLS SLYKKNIQRL TKTFLTLSLQ DMASRVQLSG PQEAEKYVLH MIEDGEIFAS INQKDGMVSF HDNPEKYNNP AMLHNIDQEM LKCIELDERL KAMDQEITVN PQFVQKSMGS QEDDSGNKPS SYS
Explore COP9 signalosome complex subunit 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets